Heart failure can occur if the heart cannot pump (systolic) or fill (diastolic) adequately. Reducing a protein found in the mitochondria of cardiac muscle cells initiates cardiac dysfunction and heart failure.
This finding that could provide insight into new treatments for cardiovascular diseases, a study led by Georgia State University has shown. The researchers discovered that reducing an outer mitochondrial membrane protein, FUN14 domain containing 1 (FUNDC1), in cardiac muscle cells, also known as cardiomyocytes, activates and worsens cardiac dysfunction.
Heart Failure Cases Increase In UK, Especially Among The Poor
Due to an increase in the number of older people and the incidence of cancer, there has been an increase in heart failure cases.
Advertisement
‘Myocardium, the muscular wall of the heart, is a high-energy-demand tissue and, mitochondria play a central role in maintaining optimal cardiac performance.’
Tweet it Now
Also, disrupting how FUNDC1 binds to a particular receptor inhibited the release of calcium from another cell structure, the endoplasmic reticulum (ER), into the mitochondria of these cells and resulted in mitochondrial dysfunction, cardiac dysfunction and heart failure. The findings are published in the journal Circulation.
Mitochondria play numerous roles in the body, including energy production, reactive oxygen species generation and signal transduction. Because the myocardium, the muscular wall of the heart, is a high-energy-demand tissue, mitochondria play a central role in maintaining optimal cardiac performance. Growing evidence suggests deregulated mitochondrial activity plays a causative role in cardiovascular diseases.
![Treating Heart Failure Requires an Integrated Study of the Heart, Spleen, and Kidney]( "Treating Heart Failure Requires an Integrated Study of the Heart, Spleen, and Kidney")
Study examines changes in the spleen and kidney that occur simultaneously during heart attacks.
In the body, mitochondria and ER are interconnected and form their own endomembrane networks. The points where mitochondria and ER make physical contact and communicate are known as mitochondria-associated ER membranes (MAMs). MAMs play a major role in regulating the transfer of calcium between ER and mitochondria. Dysfunctional MAMs are involved in several neuronal disorders, including Alzheimer's disease and Parkinson's disease. Until now, the role of MAMs in cardiac pathologies has not been well understood.
"Our study found the formation of MAMs mediated by the mitochondrial membrane protein FUNDC1 was significantly suppressed in patients with heart failure, which provides evidence that FUNDC1 and MAMs actively participate in the development of heart failure," said Dr. Ming-Hui Zou, director of the Center for Molecular and Translational Medicine at Georgia State and a Georgia Research Alliance Eminent Scholar in Molecular Medicine. "This work has important clinical implications and provides support that restoring proper function of MAMs may be a novel target for treating heart failure."
The researchers used mouse neonatal cardiomyocytes, mice with a genetic deletion of the FUNDC1 gene, control mice with no genetic deficiencies and the cardiac tissues of patients with heart failure.
The cardiac functions of the mice were monitored using echocardiography at 10 weeks of age. Mice with the genetic deletion of FUNDC1 had markedly reduced ventricular filling velocities, prolonged left ventricular isovolumic relaxation time, diastolic dysfunction, decreased cardiac output (which indicates impaired systolic functions) and interstitial fibrosis of the myocardium, among other issues. The mitochondria in the hearts of mice with FUNDC1 gene deletion were larger and more elongated, a 2.5-fold increase of size compared to mitochondria in the control mice.
To determine if FUNDC1 reduction occurred in human hearts and contributed to heart failure in patients, the researchers examined four heart specimens from heart failure patients and four heart specimens from control donors. They found the levels of FUNDC1 were significantly reduced in patients with heart failure compared to control donors. Also, the contact between ER and mitochondria in failed hearts was significantly reduced. In addition, the mitochondria in heart failure hearts were more elongated compared to those in control donors.
Source: Eurekalert
Treating Heart Failure Requires an Integrated Study of the Heart, Spleen, and Kidney
Study examines changes in the spleen and kidney that occur simultaneously during heart attacks.
Advertisement
In the body, mitochondria and ER are interconnected and form their own endomembrane networks. The points where mitochondria and ER make physical contact and communicate are known as mitochondria-associated ER membranes (MAMs). MAMs play a major role in regulating the transfer of calcium between ER and mitochondria. Dysfunctional MAMs are involved in several neuronal disorders, including Alzheimer's disease and Parkinson's disease. Until now, the role of MAMs in cardiac pathologies has not been well understood.
"Our study found the formation of MAMs mediated by the mitochondrial membrane protein FUNDC1 was significantly suppressed in patients with heart failure, which provides evidence that FUNDC1 and MAMs actively participate in the development of heart failure," said Dr. Ming-Hui Zou, director of the Center for Molecular and Translational Medicine at Georgia State and a Georgia Research Alliance Eminent Scholar in Molecular Medicine. "This work has important clinical implications and provides support that restoring proper function of MAMs may be a novel target for treating heart failure."
The researchers used mouse neonatal cardiomyocytes, mice with a genetic deletion of the FUNDC1 gene, control mice with no genetic deficiencies and the cardiac tissues of patients with heart failure.
The cardiac functions of the mice were monitored using echocardiography at 10 weeks of age. Mice with the genetic deletion of FUNDC1 had markedly reduced ventricular filling velocities, prolonged left ventricular isovolumic relaxation time, diastolic dysfunction, decreased cardiac output (which indicates impaired systolic functions) and interstitial fibrosis of the myocardium, among other issues. The mitochondria in the hearts of mice with FUNDC1 gene deletion were larger and more elongated, a 2.5-fold increase of size compared to mitochondria in the control mice.
To determine if FUNDC1 reduction occurred in human hearts and contributed to heart failure in patients, the researchers examined four heart specimens from heart failure patients and four heart specimens from control donors. They found the levels of FUNDC1 were significantly reduced in patients with heart failure compared to control donors. Also, the contact between ER and mitochondria in failed hearts was significantly reduced. In addition, the mitochondria in heart failure hearts were more elongated compared to those in control donors.
Source: Eurekalert
Acute Heart Failure Can be Treated by a New Minimally Invasive Procedure
A percutaneous auxiliary artificial heart procedure, a minimally invasive procedure can provide immediate relief to Acute heart failure cases
Advertisement
 Heart Failure Patients Receive Less Palliative CareWith improved education, cardiologists and primary care clinicians can integrate palliative care techniques in their everyday practice. | Advertisement
|
Advertisement
Recommended Readings
Latest Heart Disease News
In the past two years, the Bangalore PCAD registry reported over 2,500 heart attack cases in individuals under 40, with 1,250 of them under 35.
World Heart Day 2023: Many women face difficulties when it comes to accessing healthcare services, including cardiovascular screening, preventive care, and treatment.
Midlife women approaching menopause experience hot flashes which are linked to increased systemic inflammation, a risk factor for heart diseases.
Patients with tachycardia (fast heart rate) can quickly return to normal heart rhythm with a self-administered etripamil nasal spray.
Every year on September 29, World Heart Day is observed to promote awareness of heart-related diseases and seek solutions for heart disease prevention and management.
